Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06711705 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06711705 · ClinicalTrials.gov record · last posted 2026-02-20

Elranatamab in Relapsed/Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 2
Started2024-12-18
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-11-26; most recent amendment 2026-02-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-02-07
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06711705
Lead Sponsor University of California, San Diego
Conditions Multiple Myeloma
Enrollment 33 participants
Start Date 2024-12-18
Primary Completion 2029-12 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-20